References

  1. Rodriguez-Roisin R, Anzueto A, Bourbeau J, et al; GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2009). Global Initiative for Chronic Obstructive Lung Disease website: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2003. Accessed March 8, 2010.
  2. Gross NJ, Nelson HS, Lapidus RJ, et al; Formoterol Study Group. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008;102(2):189-197.
  3. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127(1):335-371.
  4. Broeders NE, Sanchis J, Levy ML, Crompton GK, Dekhuijzen PN; ADMIT Working Group. The ADMIT series—issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J. 2009;18(2):76-82.
  5. Kleinschmidt P. Chronic obstructive pulmonary disease and emphysema. eMedicine website. http://emedicine.medscape.com/article/807143-overview. Accessed April 19, 2010.
  6. Chronic obstructive pulmonary disease. In: Porter RS, Kaplan JL, eds. The Merck Manuals Online Medical Library. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2010. http://www.merck.com/mmpe/sec05/ch049/ch049a.html. Accessed April 19, 2010.
  7. American Thoracic Society. Quality of life resource: St. George's Respiratory Questionnaire. http://atsqol.org/sections/instruments/pt/pages/george.html. Accessed June 4, 2008.
  8. Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K; Formoterol Study Group. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial [published correction appears in Clin Ther. 2009;31(4):920. doi:10.1016/j.clinthera.2009.4.001]. Clin Ther. 2007;29(10):2167-2178. doi:10.1016/j.clinthera.2007.10.007.
  9. PERFOROMIST® Prescribing Information. Napa, CA Dey Pharma, L.P., 2010
  10. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593-604.
  11. Zarowitz BJ. Nebulized respiratory medications: friend or foe? Geriatr Nurs. 2009;30:45-49.
  12. Onoue S, Misaka S, Kawabata Y, et al. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opin Drug Deliv. 2009;6:793-811.
  13. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50:1313-1321.
  14. Medication Guide: PERFOROMIST® (formoterol fumarate) Inhalation Solution. Location City, State: Dey Pharma, L.P.; 2008.
  15. Donohue JF et al. Ther Adv Respir Dis. 2008;2:199-208.
  16. CDC National Vital Statistics Reports for 2005. 56 (10); April 2008. Accessed at http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_10.pdf
  17. Mannino DM et al. MMWR Surveill Summ. 2002;51:1-13.
  18. Luppi F et al. Proc Am Thorac Soc. 2008;5:848-856.
  19. CMS site data CMS. http://www.cms/hhs.gov/states/MDSPubQIandResReport. Q408. Accessed 3/2010.
  20. NAEPP Expert Panel Report 3: Guidelines for Diagnosis and Management of Asthma.
  21. Jemal A et al. JAMA. 2005;294:1255-1259.
  22. American Lung Association: Epidemiology and Statistics Unit-Research and Program Services Division. Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality April 2009 (ALA-lungusa.com)
  23. American Thoracic Society. Standards for Diagnosis and Management of COPD. 2004 (ATS-thoracic.org)
  24. Data on file.
  25. Van der Palen, J, Klein JJ, Kerkhoff AHM, van Herwaarden CLA. Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease. Thorax 1995; 50:1183-1187.
  26. Van der Palen J, Klein JJ, Kerkhoff AHM, van Herwaarden CLA, Seydel ER. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Pt Ed Couns 1997;32:S87-S95.
  27. J Jones V, Fernandez C, Diggory P. A comparison of large volume spacer, breath-activated and dry powder Inhalers in older people. Age Aging 1999; 28:481-484.
  28. Van Beerendonk I. Jour of Asthma 35(3), 273-279 (1998)
  29. Spirometry for Diagnosis of COPD: Insert for GOLD Pocket Guide. Accessed from Global Initiative for Chronic Obstructive Lung Disease website: http://www.goldcopd.com/GuidelineItem.asp?intId=1118. Accessed October 1, 2010.

Please see accompanying full Prescribing Information, including Boxed Warning.

Indication

PERFOROMIST® (formoterol fumarate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

WARNING: ASTHMA-RELATED DEATH

Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including formoterol, the active ingredient in PERFOROMIST Inhalation Solution. The safety and efficacy of PERFOROMIST in patients with asthma have not been established. All LABA, including PERFOROMIST, are contraindicated in patients with asthma without use of a long-term asthma control medication (see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS).

Important Safety Information

PERFOROMIST Inhalation Solution should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm.

PERFOROMIST Inhalation Solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.

PERFOROMIST Inhalation Solution should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines.

WARNINGS AND PRECAUTIONS

Deterioration of Disease and Acute Episodes
PERFOROMIST Inhalation Solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. PERFOROMIST Inhalation Solution should not be used for the relief of acute symptoms, ie, as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist

Excessive Use of PERFOROMIST Inhalation Solution and Use With Other Long-Acting Beta2-Agonists
PERFOROMIST Inhalation Solution should not be used more often, at higher doses than recommended, or in conjunction with other inhaled, long-acting beta2-agonists, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs

Paradoxical Bronchospasm
As with other inhaled beta2-agonists, PERFOROMIST Inhalation Solution can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, PERFOROMIST Inhalation Solution should be discontinued immediately and alternative therapy instituted

Cardiovascular Effects
PERFOROMIST Inhalation Solution, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic and/or diastolic blood pressure, and/or symptoms.

PERFOROMIST Inhalation Solution should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines.

Coexisting Conditions
PERFOROMIST Inhalation Solution, like other sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to sympathomimetic amines. Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis

DRUG INTERACTIONS

MAO Inhibitors, Tricyclic Antidepressants and QTc Prolonging Drugs
PERFOROMIST Inhalation Solution, as with other beta2-agonists, should be used with extreme caution in patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.